For pharma & researchers
Better data for faster, more successful trials
Oku detects disease biomarkers from routine eye exams. Earlier and precise AI-enabled retinal imaging analysis mean data-driven trial design, enriched cohorts, and faster path to approval.
Join the Network
Most trial failures are not scientific failures
Drug development has lengthy timelines and low success rates. Treatment-naïve, early disease, or enriched populations with real disease progression are seeking treatment at the point of care. What has been missing in the field is the infrastructure to find these patients at scale, through referral channels embedded in routine care, generating longitudinal data and advanced imaging analysis that compounds with every visit.
of drugs entering Phase I trials never reach approval,1 and success rates are falling at every clinical phase.2
cost to bring a single drug to market3
average development timeline4
One exam. A more connected path to care.
Risk caught too late, referrals that never close, patients lost between providers. Each Oku solution addresses a specific break in the care pathway, and they compound: the same exam that surfaces chronic risk connects the patient to the right provider and keeps the whole care team informed.
Built to accelerate drug development
Oku is designed as a connected care infrastructure, not a data vendor that ships files and steps back. A partnership with Oku means access to the data network, integration with existing clinical workflows, and the ability to develop trial enrichment criteria, trial endpoints and innovative trial designs anchored in real-world data. Reading center precision. Smarter patient finding. Real-world evidence.
( 01 )
Real-World Data and Evidence
License longitudinal, AI-labeled ocular data for your own research, or bring Oku the scientific question and get the real-world evidence for data-driven trial design, post-market surveillance, or commercial development.
( 02 )
Patient and Site Finding
AI-enabled trial-specific patient screening runs in the primary eye care and primary care settings where early-stage, treatment-naive, or enriched patients are seen every day. A larger patient pool, fewer screen failures, faster enrollment.
( 03 )
Expert Reading Center Services
Centralized adjudication of imaging and functional trial data using state-of-the-art methodologies. The hybrid model, AI-enabled readings verified by human experts, reduces variability, safeguards data integrity, and accelerates regulatory submissions.
Leveraging ophthalmic images and data to expedite new therapeutics
The same routine eye exam carries data across therapeutic indications. One clinical network. Multiple scientific discovery pathways.
Peer-reviewed oculomics publications have grown more than sixtyfold since 2020.1
See the ResearchOcular diseases
Diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, intermediate age-related macular degeneration and geographic atrophy, inherited retinal diseases, glaucoma, and other core ophthalmic indications, already the most mature and validated data layer in the network.
Cardiovascular, renal & metabolic disease
Retinal microvascular changes detectable through the same eye exam that signal cardiovascular, renal and metabolic risk predictions, often years before a systemic diagnosis is made, an association validated across a rapidly growing body of peer-reviewed research.
Neurodegenerative disease
Multimodal retinal imaging analysis, including microvascular or retinal ganglion cell and nerve fiber layer changes that are associated with neurodegenerative conditions, detectable through the same eye exam, and among the earliest biomarkers that researchers are studying for neurodegenerative disease detection.
Built to your protocol
Oku identifies and connects the right patients for your trial or cohort, drawing on the same longitudinal data powering every category above.
Drug Lifecycle
One data layer, every stage of clinical drug development
Most data vendors solve for narrow trial needs only. Oku infrastructure and network data creates value from drug discovery and trial design through post-market surveillance.
Drug Discovery & Trial Design
Validate biomarkers and prioritize indications with real-world ocular data, from early-stage Phase 1 or 2 trials to Phase 3 pivotal trials. Refine eligibility criteria, trial design, and endpoint analysis based on real world evidence, not past assumptions from the general literature.
Recruitment & Enrollment
Recruit treatment-naive, early disease cases, or enriched populations by identifying eligible patients where they already are, across primary eye care and primary care. A larger patient pool, fewer screen failures, faster enrollment.
Imaging & Endpoint Analysis
Standardized imaging endpoints, read by AI and verified by experts. Audit-ready data with full provenance, submission-grade from collection.
Post-Market Surveillance & Access Claims
Real-world data from transversal or longitudinal cohorts, matching or expanding the trial population. Track outcomes and safety signals, and support label claims at scale without Registries or Phase 4 trials.
Compliance built in, not bolted on
Most reading centers retrofit compliance onto legacy workflows after the fact. Oku was architected compliance-native from day one, so every scan, dataset, and output is submission-ready by design, not by patchwork.
That difference shows up in the pipeline: fewer remediation cycles, fewer surprises at audit, and data your regulatory team doesn't have to re-verify before it can be used.
Data-driven, faster trials, higher probability of technical success
See how real-world data can support your pipeline